Mesoblast 주식 가격. MESO - 주식 시세, 차트, 과거 거래, 주식 채팅, 재무.

실시간 스트리밍 인용문, 아이디어 및 실시간 토론을 위한 허브

프리미엄

가격

19.20

매수가

18.95

매도가

19.79

거래량

295,743

19.20 일간 변동폭 20.20

0.00 52주 범위 0.00

market_cap

2.192B

전일 종가

19.55

개장가

19.20

최근 거래 시간

100

19.2

(formt)

마지막 거래 시간

재정 규모

US$ 5,833,298

VWAP

19.7242

평균 볼륨(3m)

발행 주식

114,178,411

배당수익률

주가수익률

-4.08

주당순이익(EPS)

-0.77

매출

9.25M

순이익

-87.96M

Mesoblast Ltd is a clinical-stage biotechnology company. It develops and commercializes innovative allogeneic cellular medicines to treat complex diseases resistant to the conventional standard of care. Its portfolio of Phase 3 product candidates comprises remestemcel-L for the treatment of steroid-... Mesoblast Ltd is a clinical-stage biotechnology company. It develops and commercializes innovative allogeneic cellular medicines to treat complex diseases resistant to the conventional standard of care. Its portfolio of Phase 3 product candidates comprises remestemcel-L for the treatment of steroid-refractory acute graft versus host disease (SR-aGVHD), and for moderate to severe acute respiratory distress syndrome (ARDS) and others. 더 보기

섹터

Biological Pds,ex Diagnstics

산업

Biological Pds,ex Diagnstics

웹사이트

www.mesoblast.com

본부

Melbourne, Victoria, Aus

설립됨

Mesoblast Limited is listed in the Biological Pds,ex Diagnstics sector of the 나스닥 with ticker MESO. The last closing price for Mesoblast was US$19.55. Over the last year, Mesoblast shares have traded in a share price range of US$ 0.00 to US$ 0.00.

Mesoblast currently has 114,178,411 shares in issue. The market capitalisation of Mesoblast is US$2.23 billion. Mesoblast has a price to earnings ratio (PE ratio) of -4.08.

Ryoncil® Commercial Launch Update and Product Pipeline

NEW YORK, Jan. 30, 2025 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided an update on the...

Appendix 4C Quarterly Activity Report for Quarter Ended December 31, 2024

NEW YORK, Jan. 30, 2025 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided highlights of its...

Mesoblast’s RYONCIL® is the First U.S. FDA-Approved Mesenchymal Stromal Cell (MSC) Therapy

RYONCIL (remestemcel-L) is the first MSC product approved by FDA for any indication.RYONCIL is the first FDA-approved therapy for children aged 2 months and older, including adolescents and...

Mesoblast to be Added to Nasdaq Biotechnology Index

NEW YORK, Dec. 18, 2024 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced its upcoming...

Form F-3 - Registration statement by foreign private issuers

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

FDA Grants Revascor® (Rexlemestrocel-L) Regenerative Medicine Advanced Therapy (RMAT) Designation in Children with Congenital Heart Disease

NEW YORK, Dec. 04, 2024 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced the United States...

기간	변동	변동 %	시가	고가	저가	평균 일일 거래량	VWAP
1	0	0	0	0	0	0	0	DR
4	0	0	0	0	0	0	0	DR
12	0	0	0	0	0	0	0	DR
26	0	0	0	0	0	0	0	DR
52	0	0	0	0	0	0	0	DR
156	0	0	0	0	0	0	0	DR
260	0	0	0	0	0	0	0	DR

MESO - Frequently Asked Questions (FAQ)

What is the current Mesoblast share price?

The current share price of Mesoblast is US$ 19.20

How many Mesoblast shares are in issue?

Mesoblast has 114,178,411 shares in issue

What is the market cap of Mesoblast?

The market capitalisation of Mesoblast is USD 2.23B

What is the 1 year trading range for Mesoblast share price?

Mesoblast has traded in the range of US$ 0.00 to US$ 0.00 during the past year

What is the PE ratio of Mesoblast?

The price to earnings ratio of Mesoblast is -4.08

What is the cash to sales ratio of Mesoblast?

The cash to sales ratio of Mesoblast is 38.77

What is the reporting currency for Mesoblast?

Mesoblast reports financial results in USD

What is the latest annual turnover for Mesoblast?

The latest annual turnover of Mesoblast is USD 9.25M

What is the latest annual profit for Mesoblast?

The latest annual profit of Mesoblast is USD -87.96M

What is the registered address of Mesoblast?

The registered address for Mesoblast is LEVEL 38, 55 COLLINS STREET, MELBOURNE, VICTORIA, 3000

What is the Mesoblast website address?

The website address for Mesoblast is www.mesoblast.com

Which industry sector does Mesoblast operate in?

Mesoblast operates in the BIOLOGICAL PDS,EX DIAGNSTICS sector

가장 활성
% 상승자
% 패자

기호	가격	볼륨
FOXXFoxx Development Holdings Inc	US$ 6.355 (119.90%)	33.52M
BHILBenson Hill Inc	US$ 3.925 (118.06%)	13.52M
TECXTectonic Therapeutic Inc	US$ 55.18 (114.54%)	5.46M
AMODAlpha Modus Holdings Inc	US$ 3.2299 (109.73%)	125.47M
DOMHDominari Holdings Inc	US$ 3.61 (59.03%)	4.24M
CLEUChina Liberal Education Holdings Ltd	US$ 0.149 (-98.08%)	311.38M
CRGXCARGO Therapeutics Inc	US$ 3.39 (-74.30%)	21.21M
TDTHTrident Digital Tech Holdings Ltd	US$ 1.0159 (-58.87%)	2.46M
EVTVEnvirotech Vehicles Inc	US$ 0.338202 (-49.30%)	4.78M
IRWDIronwood Pharmaceuticals Inc	US$ 2.29 (-38.44%)	10.53M
NVDANVIDIA Corporation	US$ 124.65 (0.77%)	392.11M
CLEUChina Liberal Education Holdings Ltd	US$ 0.149 (-98.08%)	311.38M
MGOLMGO Global Inc	US$ 0.1199 (17.90%)	166.88M
SPGCSacks Parente Golf Inc	US$ 0.93 (57.63%)	129.08M
RIMEAlgorhythm Holdings Inc	US$ 0.02465 (-5.19%)	126.09M